Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry

Circ Cardiovasc Qual Outcomes. 2018 Mar;11(3):e004249. doi: 10.1161/CIRCOUTCOMES.117.004249.

¹ From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.). navar006@dm.duke.edu.
² From the Department of Medicine (Cardiology), Duke Clinical Research Institute, Durham, NC (A.M.N., E.D.P., S.L., T.Y.W. M.G.N.); Department of Epidemiology, University of Iowa (J.G.R.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.L.R.); Washington University, St. Louis, MO (A.C.G.); VA Medical Center and Baylor College of Medicine, Houston, TX (S.V.); Department of Medicine, Emory University, Atlanta, GA (P.W.F.W.); Sanofi Pharmaceuticals, Bridgewater, NJ (L.V.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (J.E.).

No abstract available

Keywords: Hydroxymethylglutaryl-CoA reductase inhibitors; cardiovascular disease; drug-related side effects and adverse reactions; nocebo effect.

Publication types